1. Home
  2. ALT vs FDMT Comparison

ALT vs FDMT Comparison

Compare ALT & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • FDMT
  • Stock Information
  • Founded
  • ALT 1997
  • FDMT 2013
  • Country
  • ALT United States
  • FDMT United States
  • Employees
  • ALT N/A
  • FDMT N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • FDMT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALT Health Care
  • FDMT Health Care
  • Exchange
  • ALT Nasdaq
  • FDMT Nasdaq
  • Market Cap
  • ALT 333.6M
  • FDMT 391.8M
  • IPO Year
  • ALT N/A
  • FDMT 2020
  • Fundamental
  • Price
  • ALT $3.93
  • FDMT $9.61
  • Analyst Decision
  • ALT Strong Buy
  • FDMT Strong Buy
  • Analyst Count
  • ALT 6
  • FDMT 8
  • Target Price
  • ALT $17.40
  • FDMT $30.63
  • AVG Volume (30 Days)
  • ALT 3.0M
  • FDMT 688.5K
  • Earning Date
  • ALT 11-11-2025
  • FDMT 11-12-2025
  • Dividend Yield
  • ALT N/A
  • FDMT N/A
  • EPS Growth
  • ALT N/A
  • FDMT N/A
  • EPS
  • ALT N/A
  • FDMT N/A
  • Revenue
  • ALT $20,000.00
  • FDMT $33,000.00
  • Revenue This Year
  • ALT N/A
  • FDMT $9,656.76
  • Revenue Next Year
  • ALT N/A
  • FDMT N/A
  • P/E Ratio
  • ALT N/A
  • FDMT N/A
  • Revenue Growth
  • ALT N/A
  • FDMT N/A
  • 52 Week Low
  • ALT $2.90
  • FDMT $2.24
  • 52 Week High
  • ALT $11.16
  • FDMT $9.84
  • Technical
  • Relative Strength Index (RSI)
  • ALT 52.80
  • FDMT 63.90
  • Support Level
  • ALT $3.85
  • FDMT $8.11
  • Resistance Level
  • ALT $4.06
  • FDMT $9.03
  • Average True Range (ATR)
  • ALT 0.20
  • FDMT 0.52
  • MACD
  • ALT 0.02
  • FDMT -0.01
  • Stochastic Oscillator
  • ALT 57.35
  • FDMT 76.79

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About FDMT 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Share on Social Networks: